Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups

PURPOSE: Assessing impact of poor accrual on premature trial closure requires a relevant metric. We propose defining accrual sufficiency on apparent ability to address primary endpoints (PE) rather than attaining accrual targets. EXPERIMENTAL DESIGN: All phase III trials open January 1, 1993, to Dec...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Schroen, Anneke T., Petroni, Gina R., Wang, Hongkun, Thielen, Monika J., Gray, Robert, Benedetti, Jacqueline, Wang, Xiaofei F., Sargent, Daniel J., Wickerham, Donald L., Cronin, Walter, Djulbegovic, Benjamin, Slingluff, Craig L.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3977198/
https://ncbi.nlm.nih.gov/pubmed/21976533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1633
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky